Dissecting the "CHF admission": An evidence-based review of the evaluation and management of acute decompensated heart failure for the hospitalist

Journal of Hospital Medicine

Volumn 7, Issue 5, 2012, Pages 439-445

  Kransdorf, Evan P ^a   Kittleson, Michelle M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; METOLAZONE; METOPROLOL SUCCINATE; NEUROHORMONE; NITROPRUSSIDE SODIUM;

ABDOMINAL PAIN; ACUTE HEART FAILURE; ASCITES; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIURESIS; DRUG MEGADOSE; DYSPNEA; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH EDUCATION; HEART FAILURE; HEART INFARCTION; HEMODYNAMICS; HOSPITAL PERSONNEL; HUMAN; HYPERTENSION; LABORATORY TEST; LEG EDEMA; LUNG EDEMA; MEDICAL HISTORY; NAUSEA; PAROXYSMAL DYSPNEA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; THORAX PAIN; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HEART FAILURE; HOSPITALISTS; HUMANS; PATIENT ADMISSION; PROGRAM EVALUATION;

EID: 84861987928     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.1919     Document Type: Review

References (61)

1. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 2008; 52(6): 428-434.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011; 123(8): 933-944.
3. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service Program. N Engl J Med. 2009; 360(14): 1418-1428.
4. 111th Congress: 2009-2010. H.R.3590: Patient Protection and Affordable Care Act. 2009. Available at: http://www.govtrack.us/congress/bill.xpd?bill=h111-3590&tab=reports. Accessed June 21, 2011.
5. Wang CS. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005; 294(15): 1944-1956.
6. Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE Trial. Circ: Heart Fail. 2008; 1(3): 170-177.
7. Hsu R-B. Heart transplantation in patients with end-stage heart failure and cardiac ascites. Circ J. 2007; 71(11): 1744-1748.
8. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003; 41(10): 1797-1804.
9. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006; 296(18): 2217-2226.
10. Zile MR, Adamson PB, Cho YK, et al. Hemodynamic factors associated with acute decompensated heart failure: part 1-insights into pathophysiology. J Card Fail. 2011; 17(4): 282-291.
11. Maisel A, Mueller C, Adamsjr K, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9): 824-839.
12. Daniels L, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study. Am Heart J. 2006; 151(5): 999-1005.
13. Bayesgenis A, Defilippi C, Januzzijr J. Understanding amino-terminal pro-B-type natriuretic peptide in obesity. Am J Cardiol. 2008; 101(3): S89-S94.
14. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003; 41(3): 571-579.
15. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement. J Am Coll Cardiol. 2006; 47(1): 91-97.
16. Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation. 2004; 109(20): 2432-2439.
17. Gluecker T, Capasso P, Schnyder P, et al. Clinical and radiologic features of pulmonary edema. Radiographics. 1999; 19(6): 1507-1533.
18. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function. J Am Coll Cardiol. 2006; 47(1): 76-84.
19. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007; 50(8): 768-777.
20. Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail. 2007; 13(7): 569-576.
21. Department of Health and Human Services. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2008 rates. Fed Reg. 2007; 72(162): 47130-48175.
22. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol. 2009; 53(15): e1-e90.
23. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008; 168(8): 847-854.
24. Fonarow GC, Adams KF, Abraham WT, et al. ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293(5): 572-580.
25. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure. J Am Coll Cardiol. 2008; 52(5): 347-356.
26. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B -type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(19): 1943-1950.
27. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008; 358(20): 2117-2126.
28. Peacock WF, Braunwald E, Abraham W, et al. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol. 2010; 56(5): 343-351.
29. Ahmed A, Allman RM, Kiefe CI, et al. Association of consultation between generalists and cardiologists with quality and outcomes of heart failure care. Am Heart J. 2003; 145(6): 1086-1093.
30. Gheorghiade M, Filippatos G, Deluca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006; 119(12): S3-S10.
31. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998; 351(9100): 389-393.
32. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985; 102(3): 314-318.
33. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364(9): 797-805.
34. Brater DC. Diuretic therapy. N Engl J Med. 1998; 339(6): 387-395.
35. Neuberg G. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002; 144(1): 31-38.
36. Costanzo MR, Saltzberg M, O'sullivan J, Sobotka P. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005; 46(11): 2047-2051.
37. Eshaghian S, Horwich T, Fonarow G. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97(12): 1759-1764.
38. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008; 10(2): 188-195.
39. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010; 56(19): 1527-1534.
40. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6): 675-683.
41. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2008; 52(3): 190-199.
42. Fonarow G, Abraham W, Albert N, et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail. 2007; 13(9): 722-731.
43. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. J Am Coll Cardiol. 2004; 43(8): 1423-1429.
44. O'Connor C, Abraham W, Albert N, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008; 156(4): 662-673.
45. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004; 147(2): 331-338.
46. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43(1): 61-67.
47. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386): 777-781.
48. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32(6): 670-679.
49. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482-1487.
50. Ross JS, Mulvey GK, Stauffer B, et al. Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med. 2008; 168(13): 1371-1386.
51. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43(4): 635-641.
52. Michtalik HJ, Yeh H-C, Campbell CY, et al. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol. 2011; 107(8): 1191-1195.
53. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010; 303(17): 1716-1722.
54. van der Wal MHL, van VeldhuisenDJ, Veeger NJGM, Rutten FH, Jaarsma T. Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J. 2010; 31(12): 1486-1493.
55. Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010; 363(24): 2301-2309.
56. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;(8): CD007228.
57. Fonarow GC, Peterson ED. Heart failure performance measures and outcomes: real or illusory gains. JAMA. 2009; 302(7): 792-794.
58. American Medical Association's Physician Consortium for Performance Improvement (AMA-PCPI). Heart Failure Performance Measure Set. AMA-PCPI; February 17, 2011; 1-85. http://www.ama-assn.org/ama/pub/physician-resources/physician-consortium-performance-improvement.page. Accessed December 12, 2011.
59. Bonow RO, Bennett S, Casey DEJr, et al. ACC/AHA clinical performance measures for adults with chronic heart failure. J Am Coll Cardiol. 2005; 46(6): 1144-1178.
60. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007; 297(1): 61-70.
61. Hernandez AF, Hammill BG, Peterson ED, et al. Relationships between emerging measures of heart failure processes of care and clinical outcomes. Am Heart J. 2010; 159(3): 406-413.